$109.46
2.03[1.89%]
At close: Apr 26
$109.46
0[0.00%]
After Hours: 4:00PM EDT
Jazz Pharmaceuticals
(NASDAQ:JAZZ)Latest News for Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)
Jazz Pharmaceuticals Stock (NASDAQ: JAZZ)
Categories: All
Wednesday, April 10, 2024
Tuesday, April 02, 2024
Monday, March 25, 2024
Friday, March 22, 2024
Wednesday, March 20, 2024
- Truist Securities Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price TargetBenzinga Newsdesk - Mar 20, 2024, 11:50AM
- The Analyst Landscape: 12 Takes On Jazz PharmaceuticalsBenzinga Insights - Mar 20, 2024, 10:00AM
- Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $188Benzinga Newsdesk - Mar 20, 2024, 8:31AM
- Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188Benzinga Newsdesk - Mar 20, 2024, 7:58AM
- Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $220 Price TargetBenzinga Newsdesk - Mar 20, 2024, 6:39AM
Friday, March 15, 2024
Thursday, March 14, 2024
Tuesday, March 12, 2024
Monday, March 04, 2024
- CORRECTION: Jury Ruled In Favor Of Avadel With Respect To One Of The Contested PatentsBenzinga Newsdesk - Mar 4, 2024, 3:52PM
- Avadel Pharmaceuticals Issues Statement On Patent Litigation; Statement In Response To Jury Ruling In Patent Suit Brought By Jazz Pharmaceuticals Inc. Regarding LUMRYZBenzinga Newsdesk - Mar 4, 2024, 3:39PM
Thursday, February 29, 2024
- Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price TargetBenzinga Newsdesk - Feb 29, 2024, 1:13PM
- RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $195 Price TargetBenzinga Newsdesk - Feb 29, 2024, 12:02PM
- JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $170Benzinga Newsdesk - Feb 29, 2024, 11:37AM
- Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst ReviewsBenzinga Insights - Feb 29, 2024, 8:00AM
- Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $220Benzinga Newsdesk - Feb 29, 2024, 7:41AM
Wednesday, February 28, 2024
- Jazz Pharmaceuticals Sees FY24 Adj. EPS $18.15-$19.35 Vs $19.94 Est.; Revenue $4.00B-$4.20B Vs $4.088B Est.Benzinga Newsdesk - Feb 28, 2024, 4:19PM
- Recap: Jazz Pharmaceuticals Q4 EarningsBenzinga Insights - Feb 28, 2024, 4:10PM
- Jazz Pharmaceuticals Q4 2023 Adj EPS $5.02 Misses $5.18 Estimate, Sales $1.01B Beat $1.00B EstimateBenzinga Newsdesk - Feb 28, 2024, 4:09PM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Wednesday, February 21, 2024
Wednesday, February 14, 2024
Wednesday, February 07, 2024
Wednesday, January 31, 2024
Monday, January 29, 2024
Monday, January 08, 2024
Wednesday, January 03, 2024
- US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings ExpectationsShanthi Rexaline - Jan 3, 2024, 7:28AM
- Decoding 6 Analyst Evaluations For Jazz PharmaceuticalsBenzinga Insights - Jan 3, 2024, 7:00AM
- Baird Initiates Coverage On Jazz Pharmaceuticals with Outperform Rating, Announces Price Target of $160Benzinga Newsdesk - Jan 3, 2024, 5:13AM
Friday, December 22, 2023
Thursday, December 21, 2023
- Jazz Says Phase 2 Trial Of Investigational JZP150 Did Not Meet The Key Secondary EndpointsBenzinga Newsdesk - Dec 21, 2023, 4:09PM
- Jazz Says Phase 2 Trial Of Investigational JZP150 In Adult Patients With Post-Traumatic Stress Disorder Did Not Meet The Primary EndpointBenzinga Newsdesk - Dec 21, 2023, 4:07PM
Friday, December 08, 2023
Wednesday, December 06, 2023
Monday, December 04, 2023
Friday, December 01, 2023
Thursday, November 30, 2023
- Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In CanadaJelena Martinovic - Nov 30, 2023, 11:15AM
- Jazz Pharmaceuticals Says It Will Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology MeetingsBenzinga Newsdesk - Nov 30, 2023, 7:48AM